Login to Your Account



Vascepa Decision; Approve Now or Wait for CV Outcomes?

By Catherine Shaffer
Staff Writer

Monday, October 14, 2013
The FDA released briefing documents ahead of Wednesday’s Endocrinologic and Metabolic Drugs Advisory Committee meeting to consider approval of Amarin Corp.’s Vascepa as an add-on to statin therapy for patients with mixed dyslipidemia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription